A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease
Status:
Withdrawn
Trial end date:
2023-09-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of JNJ-64304500 as add-on
therapy to standard of care (SOC) biologic treatment with anti-tumor necrosis factor alpha or
anti-interleukin 12/23 inhibitors in participants with active Crohn's disease in response but
not remission to SOC biologic therapy.